



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Assessment of Retinal Side Effects of Fingolimod (Gilenya) Used in Treatment of Multiple Sclerosis Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Ophthalmology*

By

Hala Kamal Hassan Elshahed

MB. Bch., Ain Shams University

Under supervision of

Prof. Dr. Abd El Rahman Gaber Salman

Professor of Ophthalmology

Faculty of Medicine - Ain Shams University

Prof. Dr. Thanaa Helmy Mohammed

Professor of Ophthalmology

Faculty of Medicine - Ain Shams University

Prof. Dr. Dina Abdelgawad Zamzam

Professor of Neurology

Faculty of Medicine - Ain Shams University

Dr. Randa Hesham Ali Abd Elgawad

Lecturer of Ophthalmology

Faculty of Medicine - Ain Shams University

*Faculty of Medicine
Ain Shams University
Cairo – Egypt
2021*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I feel

*always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Abd El Rahman Gaber Salman**, Professor of Ophthalmology, Faculty of Medicine - Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Thanaa Helmy Mohammed**, Professor of Ophthalmology, Faculty of Medicine - Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Prof. Dr. Dina Abdelgawad Zamzam**, Professor of Neurology, Faculty of Medicine - Ain Shams University, for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Randa Hesham Ali Abd Elgawad**, Lecturer of Ophthalmology, Faculty of Medicine - Ain Shams University, for her kindness, supervision and cooperation in this work.*

Hala Kamal

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of Figures	iv
Introduction	1
Aim of the Work.....	4
Review of Literature	
Multiple Sclerosis	5
Treatment of Multiple Sclerosis.....	22
Investigations used in multiple sclerosis.....	34
Patients and Methods.....	43
Results	51
Discussion	74
Conclusion	79
Recommendations	80
Summary	81
References	83
Arabic Summary	—

List of Abbreviations

Abb.	Full term
BCVA.....	Best Corrected Visual Acuity
BRB	Blood Retinal Barrier
CD.....	Cell Differentiation
CFT.....	Central Foveal Thickness
CIS.....	Clinically Isolated Syndrome
CNS	Central Nervous System
CSF	Cerebro Spinal Fluid
DMT.....	Disease Modifying Therapy
EBV	Epstein Barr Virus
ETDRS.....	Early Treatment Diabetic Retinopathy
FAME	Fingolimod Associated Macular Edema
FDA	Food and drug administration
FREEDOMS.....	Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis
GCC	Ganglion Cell Complex
HBV	Hepatitis B Virus
HHV.....	Human Herpes Virus
ILM.....	Internal Limiting Membrane
INO	Internuclear Ophthalmoplegia
IOP.....	Intraocular Pressure
ISCEV.....	International Society for Clinical Electrophysiology of Vision
LNs	Lymph Nodes
Log MAR.....	Logarithm of Minimal Angel of Resolution
Mac thickness.....	Macular Thickness
ME	Macular Edema
MfERG.....	Multifocal Electroretinogram
MLF	Medial Longitudinal Fasciculus
MRI.....	Magnetic Resonance Angiography

List of Abbreviations Cont...

Abb.	Full term
MS	Multiple Sclerosis
MT	Macular Thickness
OCT-A.....	Optical Coherence Tomography Angiography
OD.....	Right Eye
ON	Optic Neuritis
OS	Left Eye
PERG.....	Pattern Electroretinogram
PP	Primary Progressive
PPRF	Para Median Pontine Reticular Formation
RPE.....	Retinal Pigment Epithelium
RR	Relapsing Remitting
S1P.....	Sphingosin 1 Phosphate
SD-OCT	Spectral Domain Optical Coherence Tomography
SP	Secondary Progressive
TCM.....	Central Memory T Cells
TEM	Effector Memory T Cells
TMV.....	Total Macular Volume
TRANSFORMS..	Trial Assessing Injection Interferon vs Fingolimod Oral in Relapsing Multiple Sclerosis.
UAVA	Un Aided Visual Acuity
VOR	Vestibule-Ocular Reflex
WEBINO	Wall Eyed Bilateral Internuclear Ophthalmoplegia

List of Tables

Table No.	Title	Page No.
(1):	Localization of efferent visual disturbances in MS	16
(2):	Showing sex distribution and mean age group.....	51
(3):	Difference in BCVA pre and post treatment.	52
(4):	Difference in macular thickness pre and post treatment.....	52
(5):	Comparison between pre and post-treatment GCC.	53
(6):	Changes of P ₁ amplitude in 5 Rings of MfERG.	55
(7):	Affection in p ₅₀ latency and amplitude after treatment with fingolimod.	56
(8):	Changes in macular thickness with μm	58
(9):	The relation between Mac changes and P ₁ amplitude.	60
(10):	Correlation between BCVA changes and changes in P ₁ amplitude, P ₅₀ latency and amplitude using spearman correlation coefficient.	61

List of Figures

Fig. No.	Title	Page No.
(1):	Demyelination of nerves by MS causing interruption of nerve impulses and scaring	7
(2):	Different clinical symptoms of MS	13
(3):	INO and gaze affection.....	17
(4):	Picture of ocular movements of a patient with WEBINO	18
(5):	Patient has a long-standing right 3rd nerve palsy causing anisocoria, partial ptosis OD, mild adduction deficit OD, and moderate elevation and depression deficits OD.....	20
(6):	Fingolimod first oral treatment	26
(7):	FTY720 phosphorylation by Sphingosin kinase 2	28
(8):	Bilateral fingolimod associated macular edema	33
(9):	Michelson type interferometer	35
(10):	TD-OCT based on Michelson interferometer	36
(11):	Showing SD-OCT imaging system based on Michelson interferometer	37
(12):	Showing normal macula by OCT	38
(13):	Diagram of mfERG response to show the destination of the major features of wave front	41
(14):	NIDEK RS-3000 Advance OCT.....	46
(15):	RETI port scans 21 Roland (PERG screen).....	48
(16):	RETI port scan 21 Roland (MFERG screen).....	49
(17):	Sex distribution of study group.....	51
(18):	Bar chart of GCC before and after treatment with fingolimod.....	53
(19):	Description in P1 amplitude in 5 Rings of MfERG post treatment with fingolimod.	54
(20):	Affection in P50 latency in the study group.....	56

List of Figures Cont...

Fig. No.	Title	Page No.
(21):	Affection in P50 amplitude in the study group.	57
(22):	Changes in macular thickness.	58
(23):	The relation between Mac changes and P1 amplitude.	60
(24):	OCT macular thickness of right eye before and after treatment of one of the studied cases with normal macular thickness.	62
(25):	OCT map show MAC thickness (A) before treatment and (B) after treatment.	63
(26):	PERG of right eye of one of studied cases revealed decrease P50 amplitude and delayed latency of same previous patient.	64
(27):	MfERG right eye of one of the studied cases with reduction of P1 amplitude in ring 1 and ring 2 of the same previous patient.	65
(28):	OCT macular thickness of left eye before and after treatment of one of the studied cases with normal macular thickness.	66
(29):	OCT map for CFT (A) before treatment and (B) after treatment.	67
(30):	PERG of left eye of the same previous patient revealed moderately formed P50 amplitude and delayed latency.	68
(31):	MfERG left eye of one of the same previous patient revealed mild reduction of P1 amplitude in ring 1 and ring 2.	69
(32):	OCT macular thickness of right eye after treatment of one of the studied cases with normal macular thickness.	70

List of Figures Cont...

Fig. No.	Title	Page No.
(33):	OCT map for macular thickness before and after treatment, (A) before treatment and (B) after treatment.	71
(34):	PERG of left eye of the same previous patient revealed moderately formed P50 with mild latency delay and normal amplitude.....	72
(35):	MfERG left eye of one of the same previous patient revealed mild reduced P1 amplitude in ring 1 and ring 2, with within normal amplitude in ring 3, 4 of the same previous patient.	73

Introduction

Multiple sclerosis (MS) is an inflammatory demyelinating disease which targets the central nervous system in a delayed-type hypersensitivity reaction (*Höftberger and Lassmann, 2018*).

Although the clinical presentation and course of the disease are extremely variable, several disease types can be recognized, including relapsing remitting (RR), primary progressive (PP), secondary progressive (SP) MS and clinically isolated syndrome (CIS) (*Lublin, 2014*).

Visual troubles are encountered in multiple sclerosis (MS), and include problems with how affected individuals see the world (afferent visual pathway symptoms) and how their eyes move together (efferent visual pathway disorders). Optic neuritis is the most common afferent visual pathway manifestation of MS, from which visual recovery is frequently incomplete. Visual field abnormalities caused by injuries in retrochiasmal or retrogeniculate areas of afferent visual pathway also occur. Efferent pathway lesions producing ocular misalignment and nystagmus may produce diplopia and oscillopsia (*Costello, 2016*).

The modern era of multiple sclerosis (MS) treatment (disease-modifying therapies) began 25 years ago, with approval of interferon beta and glatiramer acetate for the

treatment of relapsing-remitting MS. Ten years later, the first monoclonal antibody natalizumab, followed by a third significant landmark with the introduction of oral medications, primarily fingolimod and then triflunomide, dimethyl fumarate and cladribine (*Tintore et al., 2019*).

Fingolimod (Gilenya) is a sphingosine-1- phosphate receptor modulator which is the first US Food and Drug Administration (FDA) approved oral drug for treatment of relapsing remitting forms of multiple sclerosis, its dose is 0.25 to 0.50 mg to reduce the frequency of clinical exacerbations and delay accumulation of physical disability. It has side effects like decrease heart rate, increase blood pressure, increase risk of serious infections (leuco-encephalopathy), breathing problems, increase risk of skin cancer (basal cell carcinoma and melanoma) also cause macular edema by 3 to 4 months after starting treatment, macular edema is dose dependent and reversible (*Schelenz et al., 2018*).

There are two recent phase 3 clinical studies TRANSFORMS (Trial Assessing injectable interferon vs. Fingolimod Oral in RRMS) and FREEDOMS (Fingolimod Research Evaluating Effects of Daily Oral Therapy in MS) demonstrated a significant decrease in the annualized relapse rate in patients with relapsing remitting MS on oral fingolimod, compared to once weekly interferon B1a and placebo (*Cugati et al., 2014*).